What “sublingual semaglutide” actually means
Sublingual semaglutide refers to a compounded formulation of the GLP-1 receptor agonist semaglutide designed to dissolve under the tongue. It is distinct from Rybelsus, Novo Nordisk’s FDA-approved oral semaglutide tablet, which is swallowed whole with water on an empty stomach and uses a different absorption-enhancer technology (SNAC).
Compounded sublingual preparations are prepared by licensed 503A compounding pharmacies in the USA under a valid clinician prescription. They are not FDA-approved drug products — they are patient-specific compounded preparations. Understanding that distinction is important before comparing the two routes directly.
How does bioavailability differ between the two routes?
Bioavailability is the fraction of a drug dose that reaches systemic circulation in active form. It is the single most important pharmacokinetic number when comparing delivery routes, because it determines how much of the stated dose actually gets to work.
Injectable semaglutide
Subcutaneous injectable semaglutide achieves approximately 89% bioavailability. After a subcutaneous injection, the drug is absorbed through local capillary and lymphatic networks and enters systemic circulation without passing through the GI tract or the hepatic first-pass metabolism. This is why injectable semaglutide can be dosed in micrograms and milligrams with high predictability.
The STEP clinical trial program, which demonstrated meaningful weight outcomes with injectable semaglutide, used subcutaneous weekly doses titrated from 0.25 mg to 2.4 mg. The pharmacokinetics of that route are well characterized across thousands of participants.
Oral and sublingual semaglutide
Oral peptide bioavailability is notoriously low. Peptides are chains of amino acids — the digestive tract is designed to break down amino acid chains, which is the opposite of absorption. GI enzymes and the acidic environment of the stomach degrade most peptides before they can be absorbed, and the intestinal wall is a further barrier.
Rybelsus (oral tablet) addresses this by combining semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that locally raises gastric pH and transiently increases gastric permeability near the point of absorption. Even with SNAC, oral semaglutide’s absolute bioavailability is approximately 1%. The clinical doses of Rybelsus (7 mg and 14 mg) reflect that low absorption fraction — they are roughly 5 to 10 times higher than injectable doses for comparable systemic exposure.
Compounded sublingual formulations bypass gastric acid (the sublingual mucosa is thinner and more permeable than intestinal mucosa), but semaglutide’s molecular weight and hydrophilicity still limit transmucosal absorption. Compounders typically include permeation enhancers (cyclodextrins, DMSO, or similar agents) to improve uptake. Large-scale pharmacokinetic studies comparing compounded sublingual to injectable semaglutide in humans are not yet published — this is a meaningful data gap.
What do clinical trials show for each semaglutide delivery route?
For injectable semaglutide, the evidence base for weight management is among the strongest in the GLP-1 class. STEP 1 through STEP 4 enrolled thousands of participants and demonstrated consistent effects across populations including adults with overweight or obesity and those with type 2 diabetes.
For compounded sublingual semaglutide specifically, there are no published large randomized controlled trials as of mid-2026. Clinical use is growing in the compounding-pharmacy telehealth space, but systematic efficacy and safety data for the sublingual route remains limited to smaller case series and prescriber experience. Clinicians who prescribe it do so based on pharmacological reasoning and patient preference, not a dedicated trial program.
Rybelsus (oral tablet) does have trial data — PIONEER 6 and others — but those results apply to the FDA-approved tablet with SNAC, not to compounded sublingual preparations. Drawing inferences from Rybelsus data to inform expectations from a compounded sublingual formulation requires care.
The injectable route carries the weight-management trial evidence; the sublingual route trades that certainty for no needle.
Is compounded sublingual semaglutide legal in 2026?
Start with how a compounded preparation reaches a patient at all, sublingual or injectable. A licensed clinician evaluates you and writes a prescription in your name, and under Section 503A of the FDCA a licensed pharmacy compounds that named prescription for you. Compounded preparations are not FDA-approved in any route, sublingual included, and a sublingual formula carries the additional question of how much of the dose is absorbed.
Important points for anyone considering compounded sublingual semaglutide:
- Requires a valid prescription. Compounded semaglutide in any form — injectable, sublingual, oral — requires a licensed prescriber to evaluate you and write a prescription. It cannot be sold or shipped without one.
- 503A pharmacy only. PepScribe’s standard is compounded in the USA by licensed 503A pharmacies exclusively. No hidden overseas supply chain.
- Not interchangeable with branded products. Compounded semaglutide is not a generic or biosimilar. It is a separate preparation and cannot be labeled or represented as equivalent to Ozempic or Wegovy.
- Ask what the preparation contains. Compounded formulas differ from pharmacy to pharmacy. PepScribe’s semaglutide is combined with cyanocobalamin and dosed per patient, and a sublingual preparation relies on absorption enhancers that an injection does not use. Your prescribing clinician and pharmacist can tell you exactly what you are getting.
How do injectable and sublingual semaglutide compare?
In practice, clinician choice between injectable and sublingual semaglutide comes down to a few practical considerations:
| Factor | Injectable semaglutide | Compounded sublingual |
|---|---|---|
| Bioavailability | ~89% subcutaneous | Not yet characterized in large human trials; substantially lower than injection |
| Evidence base | Extensive — STEP 1–4 trials in thousands of participants | Limited — no large RCTs; prescriber experience + pharmacological reasoning |
| Dosing frequency | Once weekly injection | Typically daily sublingual administration |
| Dose predictability | Well-characterized titration schedule (0.25 mg → 2.4 mg) | Higher inter-patient variability; doses extrapolated rather than trial-derived |
| Needle required | Yes — subcutaneous self-injection | No |
| Regulatory status | Compounded: not FDA-approved; requires 503A pharmacy + valid Rx | Not FDA-approved; requires 503A pharmacy + valid Rx |
- Needle aversion: Some patients have significant aversion to self-injection. A sublingual route removes that barrier and may improve adherence for this group, even if the per-milligram pharmacokinetics are less certain.
- Dose precision: Because injectable semaglutide bioavailability is well characterized, dose titration is more predictable. Sublingual dosing in compounded preparations involves more pharmacokinetic variability between patients and batches.
- Patient preference and lifestyle: Daily sublingual administration versus weekly injection each carries different adherence patterns. A clinician weighs which schedule a particular patient is likely to follow consistently.
- Response monitoring: Because compounded sublingual preparations have less published dose-response data, check-ins and monitoring are important to confirm the formulation is working as expected for a given patient.
What compounded semaglutide is not
To be direct about compliance matters: compounded semaglutide in any form is not an FDA-approved drug. PepScribe does not suggest that compounded semaglutide is the same as Ozempic, Wegovy, or any other branded product. We do not make disease-treatment claims. The goal of a clinician-supervised GLP-1 weight management program is to support the patient’s weight goals under medical oversight — not to treat, cure, or prevent any disease.
A licensed clinician reviews each patient individually. Not every patient is an appropriate candidate, and the clinician’s assessment is the gate to any protocol.
Frequently asked questions
Is sublingual semaglutide FDA-approved?
No. The only FDA-approved oral semaglutide formulation is Rybelsus, which is a tablet taken with water, not a sublingual (under-tongue) preparation. Compounded sublingual semaglutide is a 503A pharmacy preparation and is not FDA-approved. Subcutaneous injectable semaglutide (Ozempic, Wegovy) is FDA-approved for its labeled indications.
How does bioavailability compare between sublingual and injectable semaglutide?
Injectable semaglutide achieves near-complete subcutaneous bioavailability (approximately 89%). Sublingual compounded formulations have not been studied in large controlled trials; the oral route in general carries low semaglutide bioavailability, historically under 1% without absorption enhancers. Compounded sublingual preparations use various enhancers, but systematic comparative pharmacokinetic data in humans is limited.
Can I switch from injections to sublingual semaglutide?
This is a clinical decision that requires a licensed prescriber. Factors include your current dose, your weight management response, tolerance, and your compounding pharmacy's available formulation. A clinician can evaluate whether a route change is appropriate for your situation.
Is compounded sublingual semaglutide legal in 2026?
Compounded semaglutide is not an FDA-approved drug in any route. It is dispensed only against a valid prescription written for you by a licensed clinician, it is compounded by a licensed 503A pharmacy in the USA, and it is not interchangeable with brand-name products. Route belongs in that conversation: a sublingual preparation is a different formulation from an injection and has far less published pharmacokinetic data behind it, so ask your clinician what they are writing for you and why.
Which delivery route works better for weight management?
Injectable semaglutide has the larger published evidence base for weight management, including the STEP trial series. Compounded sublingual formulations are newer to clinical practice and carry more pharmacokinetic uncertainty. A clinician can help you weigh the trade-offs based on your preferences, needle aversion, and response goals.
